In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 mg scored, dispersible tablets, also known as paediatric DTG (pDTG). Rapid introduction and rollout of pDTG is a priority to implement the World Health Organization (WHO) guidelines and ensure that children living with HIV receive the best available first- and second-line HIV treatment as soon as possible.

To ensure children are transitioned to pDTG safely and effectively, the GAP-f pDTG Task Team developed some implementation considerations for national HIV programmes, implementing partners, and service providers.

Access the publication: